Abstract:Reduced cerebral glucose metabolism is an invariant feature in Alzheimer's disease. A key coenzyme of glucose metabolism and the active form of thiamine, thiamine diphosphate, has been shown to be significantly reduced in Alzheimer's disease. Altered blood thiamine metabolism may represent a usefulbiomarker for the diagnosis of Alzheimer's disease. Control subjects with normal cognition (n=500) and patients with Alzheimer's disease(n=110) and vascular dementia (n=53) were recruited. Blood thiamine diphosphate, thiamine monophosphate and thiamine levels as well as the activities of blood thiamine pyrophosphokinase were measured using high performance liquid chromatography. Bloodthiamine diphosphatelevels in patients with Alzheimer's disease were significantly decreased as compared with control subjects (82.31±2.23 vs. 118.60±1.12 nmol/L, P<0.001), whereas bloodthiamine monophosphateand thiamine levels were increased (5.27±0.47 vs. 3.59±0.09 nmol/L, P<0.001 and 4.21±0.42 vs. 3.41±0.11 nmol/L, P<0.01). Bloodthiamine diphosphatelevel exhibited significantly diagnostic value, with an area under receiver operating characteristic curve (AUC)of 0.871, a sensitivity of 80.00% and a specificity of 79.60%. The ratio of blood thiamine diphosphate level over seventh square root of blood thiamine level exhibited an even higher diagnostic value, with an AUC of 0.893, a sensitivity of 80.00% and a specificity of 84.00% when the cut-off point was 85.16. Over two-thirds of patients with vascular dementiawere above this cut-off point and could be differentiated from patients with Alzheimer's disease. In Alzheimer's disease patients with APOE ε4 alleles, the ratio of blood thiamine diphosphate level over seventh square root of blood thiamine level exhibited an excellent diagnostic power with an AUC of 0.906, a sensitivity of 82.69% and a specificity of 84.60%. Of mechanism, altered blood thiamine metabolism was associated with reduced activities of thiamine pyrophosphokinase in patients with Alzheiemr's disease as compared with control subjects (1.24 ± 0.06 vs. 1.44 ± 0.07, P<0.05). The patients with Alzheimer's disease manifest significant abnormality in blood thiamine metabolism as compared with normal cognitive subjects and patients with vascular dementia. Altered blood thiamine metabolism represents an ideal diagnostic biomarker for Alzheimer's disease with the reliable, non-invasive, simple to perform and inexpensive merits, and is associated with decreased thiamine pyrophosphokinase activities.

Thiamine pyrophosphokinase-1 deficiency in neurons drives Alzheimer's multiple pathophysiological alterations

Thiamine pyrophosphokinase deficiency induces Alzheimer’s pathology

P1‐078: Reduced Thiamine Diphosphate Level Contributes to Brain Glucose Hypometabolism and Neurodegeneration in Alzheimer's Disease

Thiamine Deficiency Contributes to Synapse and Neural Circuit Defects

The mechanism and consequences of amyloid-β modulating thiamine pyrophosphokinase-1 expression in microglia

Exposure to Pyrithiamine Increases β-Amyloid Accumulation, Tau Hyperphosphorylation, and Glycogen Synthase Kinase-3 Activity in the Brain

Enhanced Activities Of Blood Thiamine Diphosphatase And Monophosphatase In Alzheimer'S Disease

Thiamine Diphosphate Reduction Strongly Correlates with Brain Glucose Hypometabolism in Alzheimer’s Disease, Whereas Amyloid Deposition Does Not

Deficiency of IKKβ in neurons ameliorates Alzheimer’s disease pathology in APP- and tau-transgenic mice

Low expression of thiamine pyrophosphokinase-1 contributes to brain susceptibility to thiamine deficiency

Thiamine Deficiency Induced β-amyloid Deposition and Tau Hyperphosphorylation

Deficiency of IKK in neurons ameliorates Alzheimer's disease pathology in APP- and tau-transgenic mice

High Thiamine Diphosphate Level As a Protective Factor for Alzheimer's Disease.

Evaluation of therapeutic effects of tetramethylpyrazine nitrone in Alzheimer's disease mouse model and proteomics analysis

Discrepancy of synaptic and microtubular protein phosphorylation in the hippocampus of APP/PS1 and MAPT×P301S transgenic mice at the early stage of Alzheimer's disease

Altered blood thiamine metabolism in Alzheimer's disease

Thiamine Deficiency and Neurodegeneration: the Interplay Among Oxidative Stress, Endoplasmic Reticulum Stress, and Autophagy

Lysosomal TPCN (two pore segment channel) inhibition ameliorates beta-amyloid pathology and mitigates memory impairment in Alzheimer disease

A Novel MicroRNA-124/PTPN1 Signal Pathway Mediates Synaptic and Memory Deficits in Alzheimer's Disease

Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease

Powerful Beneficial Effects of Benfotiamine on Cognitive Impairment and Beta-Amyloid Deposition in Amyloid Precursor Protein/Presenilin-1 Transgenic Mice